Vera Therapeutics, Inc. (VERA)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Vera Therapeutics’ preliminary results for the third fiscal quarter of 2026 showed EPS of -$1.30 topped the -$1.62 estimate by $0.32, as the company reported on November 5, 2026, while net income was negative and widened year over year. Revenue came in at about $10.3 million, generating gross profit of roughly $7.0 million and a gross margin of about 68%, but operating income was -$95.7 million. Net income was -$93.7 million, down 16.7% from a year ago (when net income was -$80.3 million), and EPS was down 3.2% from -$1.26 a year earlier. Consensus for the next period calls for EPS of -$1.51 on revenue of $16.9 million.
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops medicines for serious diseases. The company is a small-cap clinical-stage drug developer focused on two lead programs, atacicept and MAU868, and operates in the United States from a base in Brisbane, California.
Today's Snapshot
VERA closed 2.4% lower at 25.58, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.3M)
930.4K
vs S&P 500 Today
Underperforming Market
-2.11%
Updated: November 18, 2026 at 21:09 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$28.11 - $35.76Sell
- RSI (14)33.82Neutral
- Stochastic %K (14, 3, 3)3.51Buy
- MACD Level (12, 26)-0.93Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.